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Pneumocystis pneumonia (PCP) caused by Pneumocystis jirovecii is one of the most common opportunistic
infections in immunosuppressed patients, particularly in patients with acquired immunodeﬁciency
syndrome (AIDS). (1/3)-b-D-glucan is a component of the cell wall of P. jirovecii and other fungi such as
Candida sp., Aspergillus sp. and Histoplasma sp. The measurement of serum (1/ 3)-b-D-glucan has been
reported to be a highly sensitive test for PCP related to human immunodeﬁciency virus (HIV-PCP). We
report a case of HIV-PCP not associated with elevated serum (1/ 3)-b-D glucan and highlight how HIV-
PCP cannot be completely ruled out if (1/ 3)-b-D glucan is negative.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pneumocystis pneumonia (PCP) caused by Pneumocystis jirovecii
is one of the most common opportunistic infections in immuno-
suppressed patients, particularly in those with acquired immuno-
deﬁciency syndrome (AIDS). (1/ 3)-b-D-glucan is a component of
the cell wall of P. jirovecii and other fungi such as Candida sp.,
Aspergillus sp. andHistoplasma sp. The bacterial burden of P. jirovecii
in PCP related to the human immunodeﬁciency virus (HIV-PCP) is
greater than in non-HIV-PCP disease. The sensitivity of serum
(1/ 3)-b-D glucan as a diagnostic test for HIV-PCP has been re-
ported to be high enough to reduce the number of cases treated
empirically and the need for a bronchoscopy, and be sufﬁcient for
ruling out PCP [1,2]. However, a small number of cases of HIV-PCP
exist not associated with elevated serum (1 / 3)-b-D glucan. To
our knowledge, a case report of HIV-PCPwithout an elevated serum
(1 / 3)-b-D glucan level has not previously been published. We
herein report a case of HIV-PCP, conﬁrmed by the identiﬁcation of P.
jirovecci cysts in bronchoalveolar lavage ﬂuid (BALF), not associated
with an elevation of serum (1/ 3)-b-D glucan.Medicine, Kobe City Medical
a-ku, Kobe, Hyogo 653-0013,
(T. Kamada), k.furuta0113@
i.jp (H. Tomioka).
Ltd. This is an open access article u2. Case report
A 40-year-old Japanese man complained to his primary care
physician of a 7 kg weight loss over a period of three months and
two days of fever with chills. The manwas subsequently referred to
our hospital. He did not complain of any headaches, nausea, vom-
iting or diarrhea and did not have a history of recent travel or close
contact with a sick person. He also lacked any relevant medical or
family history. He was a non-drinker and had a 10 pack years of
smoking history. The patient had a history of homosexual activity
and had experienced repeated, unprotected sex with unspeciﬁed
partners. His vital signs were as follows: blood pressure 132/
83 mmHg, pulse rate 122 beats/min and regular, body temperature
38.2 C, respiratory rate 14 breaths/min and oxygen saturation 97%
with ambient air. On physical examination, a furry coating was
visible on his tongue, inner cheeks and on the roof of the mouth
(Fig. 1a). Auscultation of the lungs did not reveal crackles. His car-
diac sounds were regular and murmurs were not detected. His
abdomen was soft and ﬂat; however a right hypochondrium
tenderness was detected. He did not have a perianal lesion. Labo-
ratory ﬁndings were as follows: white blood cell count (WBC) was
7240/mm3, with 77.5% neutrophils, 14.0% lymphocytes, and 8.5%
monocytes. The results of routine blood chemistry tests were
within normal range, except for lactate dehydrogenase (LDH) levels
of 257 IU/L. The C-reactive protein (CRP) serum level was elevated
to 16.8 mg/dL. Serum levels of (1 / 3)-b-D glucan (b-D glucan
Wako kit: Wako Pure Chemical Industries; Tokyo, Japan) were
below the assay's sensitivity (<5 pg/mL). Serum levels of Krebs vonnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A furry coating was visible on his tongue, inner cheeks and on the roof of the mouth (a). Abdominal CT revealed a space-occupying lesion on his liver (b).
Fig. 3. BALF smear stained with a Grocott's stain demonstrated the presence of P.
jirovecci cysts (arrow). (Grocott's stein;  40).
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normal range. Abdominal CT revealed a space-occupying lesion on
his liver (Fig. 1b). Chest radiography on the ﬁrst visit revealed
inﬁltrative shadows in the bilateral upper lung ﬁeld (Fig. 2a). Chest
high-resolution computed tomography (CT) revealed a ground-
glass opacity with multiple cysts on the bilateral upper lobes
(Fig. 2b, c). Upon further investigation, the patient was found to be
HIV-antibody positive, and a HIV RNA quantitation test revealed a
titer of 4.9 105 copies/mL, with a CD4 cell count of 48/mL. Induced
sputum smear tests were negative for bacteria, acid-fast bacilli and
P. jirovecci cysts. Cytomegalovirus (CMV) IgM antibodies were not
detected, although the patient's serum tested positive for CMV IgG
antibody. Blood cultures did not reveal bacterial growth. A CMV
antigenemia assay was negative. Antibodies to Entamoeba histo-
lytica were detected. Cells (4.8  105/mL) recovered from BALF
comprised 85%macrophages and 15% lymphocytes with a CD4/CD8
ratio of 0.03. Although the BALF smear was negative for bacteria
and acid-fast bacilli, a Grocott's stain demonstrated the presence of
P. jirovecci cysts (Fig. 3). Polymerase chain reaction testing of P.
jirovecci in BALF was also positive. We therefore diagnosed HIV-PCP
complicated by an amebic liver abscess and oral thrush. Oral
trimethoprim/sulfamethoxazole (960 mg per day), ﬂuconazole
(100 mg per day) and metronidazole (1500 mg per day) were
started on the ﬁrst day of treatment. By day 9, the patient's body
temperature had normalized, and the WBC and CRP had decreased
to 2280/mm3 (with 42.0% lymphocytes) and 1.1 mg/dL, respec-
tively. Serum (1e3) b-D glucan was still negative. The patient wasFig. 2. Chest radiography on the ﬁrst visit revealed inﬁltrative shadows in the bilateral upp
glass opacity with multiple cysts on the bilateral upper lobes (b, c).then transferred to a hospital specialized in the treatment of HIV
infections to receive antiretroviral therapy. (556words).er lung ﬁeld (a). Chest high-resolution computed tomography (CT) revealed a ground-
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In this case, although a diagnosis of HIV-PCP was conﬁrmed by
the identiﬁcation of P. jirovecci cysts in BALF, the serum (1e3)-b-D-
glucan level proved negative. PCP is a potentially life-threatening
infection that occurs in immunocompromised hosts. HIV-infected
patients with a CD4 count below 200/mL tend to suffer from PCP
[3]. In a diagnosis for PCP, the most reliable ﬁnding is histological or
cytological evidence of P. jirovecii in bronchoalveolar lavage, lung
biopsy, or sputum specimens.
The assay for serum (1/3)-b-D-glucan has been reported to be
highly sensitive for detecting this in HIV-PCP patient sera. Previous
studies, primarily retrospective case series in patients with HIV-PCP
using the Fungitell assay (East Falmouth, MA, USA), had reported a
sensitivity for serum (1/ 3)-b-D glucan ranging from 90% to 100%
[4e6]. The b-D glucan assay byWako used in our case has also been
reported to be highly sensitive, with a sensitivity of 92.3% [7]. The
high sensitivity of the (1/ 3)-b-D glucan assay is noteworthy, so a
negative value strongly supports alternative diagnoses [1]. How-
ever, it has previously been reported that even in a group with high
pre-test probability of PCP, the negative likelihood ratio of the
(1/3)-b-D glucan test is only 0.1, leading to a post-test probability
of 40% [8]. This report indicated that a negative (1/ 3)-b-D glucan
does not indicate empiric PCP treatment should be stopped,
assuming there is high clinical concern for PCP [8]. Furthermore, it
should be remembered that there are rare cases of HIV-PCP that
test negative for serum (1 / 3)-b-D glucan. For example, in 69
patients with HIV-PCP, three patients (4.3%) tested negative for
(1/ 3)-b-D glucan, although P. jiroveciiwas detected in their BALF
of these three patients [6]. Of these three patients, two presented
with a low P. jirovecii burden, as estimated by a semi-quantitative
immunoﬂuorescence method, which may account for the low
serum (1/ 3)-b-D glucan level measured [6]. The authors of this
study claimed the measured serum (1/ 3)-b-D glucan level was
negative due to a very recent infection in which the P. jirovecii load
was still small, so that the infection had not yet caused elevated
levels of serum (1/ 3)-b-D glucan [6]. In our case, it may be that
the PCP was still at an early stage of infection because the lung
lesionwas limited to the upper lobe, and respiratory symptoms had
not yet appeared. In 173 HIV-PCP patients enrolled in the AIDS
Clinical Trials Group (ACTG) A5164 (cases without an identiﬁcation
of P. jiroveciiwere also included in this study), three patients did not
show respiratory symptoms (dyspnea or shortness of breath,
coughing or production of sputum, or pleuritic chest pain) and
tested negative for serum (1/ 3)-b-D glucan [9]. However, in this
study ten patients whowere negative for serum (1/3)-b-D glucan
showed respiratory symptoms [9]. Additionally, no correlation mayexist between the level of (1/ 3)-b-D glucan and the severity of
respiratory symptoms [5]. Therefore, we should pay attention to
respiratory symptoms and any diagnosis of HIV-PCP, even if the
(1/ 3)-b-D glucan level is negative.
Cases with a continued elevated serum (1/3)-b-D glucan level
after the initiation of treatment for PCP have been reported [5].
However, in our case, the (1/ 3)-b-D glucan level was still nega-
tive after one week of treatment.
In conclusion, we report a case of HIV-PCP without any associ-
ated elevation of serum (1 / 3)-b-D glucan. Testing for serum
(1/ 3)-b-D glucan is an attractive option for a diagnosis of, or to
rule out PCP because this is an easier test than other testing mo-
dalities such as bronchoscopy. However, we have to recognize that
HIV-PCP cannot be completely ruled out when the serum (1/ 3)-
b-D glucan level is negative. (608words).Conﬂict of interest
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